Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.

ABSTRACT:

Introduction

HIV-1 remains a major global health challenge, impacting approximately 39 million people worldwide. Although antiretroviral therapy has substantially reduced HIV incidence and enhanced the quality of life for those living with HIV, adherence difficulties, limited access, and persistent stigma continue to exacerbate the disease burden. A curative or long-term immunological control strategy without continuous medication would significantly advance pandemic management. In the 2010s, technological progress led to the development of a new generation of broadly neutralizing antibodies (bNAbs) with improved potency and breadth, targeting conserved regions of the HIV-1 envelope and facilitating viral neutralization and clearance.

Methods

This review evaluates the clinic

SUBMITTER: Mahomed S 

PROVIDER: S-EPMC11972490 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature